research: reconcile all 2026 named roster URLs
This commit is contained in:
@@ -182,9 +182,9 @@ async function main() {
|
||||
assert.equal(researchResponse.status, 200, "authenticated research API");
|
||||
assert.ok(researchResponse.headers.get("cache-control")?.includes("no-store"));
|
||||
const research = await researchResponse.json();
|
||||
assert.equal(research.companies.length, 1187);
|
||||
assert.equal(research.companies.length, 1188);
|
||||
assert.equal(research.categories.length, 11);
|
||||
assert.equal(research.evidence.length, 4351);
|
||||
assert.equal(research.evidence.length, 4366);
|
||||
assert.equal(research.observations.length, 453);
|
||||
assert.equal((await request("/api/research/ai-companies", { method: "POST", headers })).status, 405);
|
||||
const researchPage = await request("/docs/other-research/ai-company-research/overview", { headers });
|
||||
|
||||
@@ -47,8 +47,8 @@ test("research revisions share the authentication database and preserve replay l
|
||||
for (let i = 0; i < 20; i++) consumeCode(config, "invalid");
|
||||
assert.equal(consumeCode(config, "invalid"), "limited");
|
||||
const initial = readResearchSnapshot();
|
||||
assert.equal(initial.companies.length, 1187);
|
||||
assert.equal(initial.evidence.length, 4351);
|
||||
assert.equal(initial.companies.length, 1188);
|
||||
assert.equal(initial.evidence.length, 4366);
|
||||
assert.equal(initial.observations.length, 453);
|
||||
assert.deepEqual(initial.candidateBatches, seed.candidateBatches, "candidate gaps persist in the same database metadata");
|
||||
assert.deepEqual(initial.directoryRechecks, seed.directoryRechecks, "follow-up classifications persist without rewriting the discovery audit");
|
||||
@@ -89,7 +89,7 @@ test("research validation rejects broken evidence and unsafe source links", () =
|
||||
test("reviews link explicit companies without turning global or excluded cases into companies", () => {
|
||||
const snapshot = structuredClone(seed) as ResearchSnapshot;
|
||||
assert.equal(snapshot.reviews.filter((r) => r.scope === "companies").length, 198);
|
||||
assert.equal(snapshot.reviews.filter((r) => r.scope === "dataset").length, 99);
|
||||
assert.equal(snapshot.reviews.filter((r) => r.scope === "dataset").length, 101);
|
||||
assert.equal(snapshot.reviews.filter((r) => r.scope === "excluded-candidate").length, 44);
|
||||
const review = snapshot.reviews.find((r) => r.id === "R4")!;
|
||||
assert.deepEqual(reviewCompanyIds(snapshot, review), ["AI007", "AI013", "AI021", "AI034"]);
|
||||
@@ -109,11 +109,11 @@ test("reviews link explicit companies without turning global or excluded cases i
|
||||
test("disclosure counts exclude client income, biographies, targets and duplicate milestones", () => {
|
||||
const snapshot = seed as ResearchSnapshot;
|
||||
const summary = categorySummary(snapshot);
|
||||
assert.equal(summary.reduce((n, c) => n + c.count, 0), 1187);
|
||||
assert.equal(summary.reduce((n, c) => n + c.count, 0), 1188);
|
||||
assert.equal(summary.reduce((n, c) => n + c.self, 0), 58);
|
||||
assert.equal(summary.reduce((n, c) => n + c.estimate, 0), 2);
|
||||
assert.equal(summary.reduce((n, c) => n + c.platform, 0), 19);
|
||||
assert.equal(summary.reduce((n, c) => n + c.unknown, 0), 1108);
|
||||
assert.equal(summary.reduce((n, c) => n + c.unknown, 0), 1109);
|
||||
assert.equal(snapshot.companies.find((c) => c.name === "Rork")?.revenueStatus, "unknown");
|
||||
assert.equal(snapshot.companies.find((c) => c.name === "Result")?.revenueStatus, "unknown");
|
||||
assert.ok(snapshot.observations.filter((o) => o.selection === "signal").every((o) => o.scope === "公司整体"));
|
||||
@@ -148,7 +148,7 @@ test("service run rates, legacy freight revenue and paid adoption do not become
|
||||
|
||||
test("technical reviews keep accessible materials separate from tested capabilities", () => {
|
||||
const snapshot = structuredClone(seed) as ResearchSnapshot;
|
||||
assert.equal(snapshot.companies.filter((c) => c.technicalReview).length, 172);
|
||||
assert.equal(snapshot.companies.filter((c) => c.technicalReview).length, 173);
|
||||
assert.equal(snapshot.companies.filter((c) => c.technicalReview?.level === "public-artifact").length, 24);
|
||||
assert.equal(snapshot.companies.filter((c) => c.technicalReview?.level === "independent-test").length, 1);
|
||||
assert.equal(snapshot.companies.find((c) => c.id === "AI051")?.revenueStatus, "unknown");
|
||||
|
||||
@@ -1,5 +1,5 @@
|
||||
{
|
||||
"version": "2026-10-31-tc26-health-4",
|
||||
"version": "2026-10-31-tc26-health-5",
|
||||
"asOf": "2026-10-31",
|
||||
"scope": "全球公开资料研究：保留首批个案，并扩展核查2025—2026八个YC批次候选池；成立年份以官方公司页面字段为依据。",
|
||||
"limitations": [
|
||||
@@ -37206,6 +37206,47 @@
|
||||
"TC26HW2-LUMENUS-5"
|
||||
]
|
||||
}
|
||||
},
|
||||
{
|
||||
"id": "TC-VALENE",
|
||||
"name": "Valene Health",
|
||||
"url": "https://valenehealth.com/",
|
||||
"channel": "S02",
|
||||
"cat": "C07",
|
||||
"year": 2025,
|
||||
"team": null,
|
||||
"location": "New York（公司/加速机构自述）",
|
||||
"business": "医疗临床、运营和财务工作流Agent：接诊、文书、预授权、依从性及收入周期。",
|
||||
"buyer": "医院/医疗系统、社区/心理健康机构、门诊及支付方",
|
||||
"delivery": "语音/文字Agent、定制工作流、EHR/门户接入；可配置预训练Agent及无代码界面自述。",
|
||||
"notes": "公司及Techstars原始名录均2025，暂按自报关联C07医疗工作流AI；法律登记/旧平台主体沿革与第三方年份差异仍待核。",
|
||||
"cohort": "2025（公司及Techstars资料，非独立注册）",
|
||||
"teamBasis": "公司11—50与Techstars1—10范围不同，4关联账户非全体员工，不取中点。",
|
||||
"price": "原始官网未披露可核当前报价/合同金额，预约演示。",
|
||||
"stage": "厂商称可部署，实际付费规模/经常合同和独立效果缺",
|
||||
"sourceType": "竞赛发现、公司/条款及Techstars名录原始资料",
|
||||
"evidenceIds": [
|
||||
"TC26AG-INDEX",
|
||||
"TC26HW5-VALENE-1",
|
||||
"TC26HW5-VALENE-2",
|
||||
"TC26HW5-VALENE-3",
|
||||
"TC26HW5-VALENE-4"
|
||||
],
|
||||
"revenueStatus": "unknown",
|
||||
"businessModel": "机构医疗工作流软件及定制接入；一次工程/人工与经常净软件费分开，SolasHealthPC/医生诊疗费不混平台费。",
|
||||
"entityBasis": "条款VALENEHEALTHINC与SolasHealthPC关系为厂商描述；2025自报与机构名录对应，第三方2024和旧平台沿革需原始登记复核。",
|
||||
"classificationBasis": "按医疗行业专业工作流归C07，不因通用Agent形式改为基础模型或通用企业助手。",
|
||||
"technicalReview": {
|
||||
"level": "description",
|
||||
"reviewedAt": "2026-10-31",
|
||||
"summary": "部署速度/患者运营改善及安全审计均厂商声明，未取得独立测试或SOC2报告；诊疗主体和软件平台区分。",
|
||||
"evidenceIds": [
|
||||
"TC26HW5-VALENE-1",
|
||||
"TC26HW5-VALENE-2",
|
||||
"TC26HW5-VALENE-3",
|
||||
"TC26HW5-VALENE-4"
|
||||
]
|
||||
}
|
||||
}
|
||||
],
|
||||
"observations": [
|
||||
@@ -92186,6 +92227,171 @@
|
||||
"kind": "官方/公司自述：2026健康组原始资料复核",
|
||||
"summary": "原首页相对链接解析为en/en路径404；正确en/order-test-kit可读，分TK保险特定患者和自费/机构入口。",
|
||||
"limitation": "没有可核公开金额或订阅期限，不将测试/保险合作年化；纠正路径不当已下单，部分适应症和参保条件不扩为人人保险覆盖。"
|
||||
},
|
||||
{
|
||||
"id": "TC26HW5-UHURA-1",
|
||||
"companyId": null,
|
||||
"title": "Uhura原始产品阶段",
|
||||
"url": "https://www.uhura.pl/",
|
||||
"publishedAt": null,
|
||||
"accessedAt": "2026-10-31",
|
||||
"kind": "官方/公司自述：2026健康组原始资料复核",
|
||||
"summary": "官网列2024可售增音器、2025电子喉、2026末个性化产品在测试；UhuraBionicsSp.z.o.o.及1000测试用户。",
|
||||
"limitation": "测试用户不等付费用户；20亿美元是行业旧设备支出主张非公司收入；ElevenLabs赠送3300万credits非收入，设备销量不全算软件ARR。"
|
||||
},
|
||||
{
|
||||
"id": "TC26HW5-UHURA-2",
|
||||
"companyId": null,
|
||||
"title": "Uhura原始公司年及销售边界",
|
||||
"url": "https://www.linkedin.com/company/uhura-bionics/?viewAsMember=true",
|
||||
"publishedAt": null,
|
||||
"accessedAt": "2026-10-31",
|
||||
"kind": "官方/公司自述：2026健康组原始资料复核",
|
||||
"summary": "公司自报2022、Warszawa及11—50范围；自述硬件销售、400余付费客户/1000余测试者及AI改进路线图。",
|
||||
"limitation": "自报非独立注册或审计；1000units/测试人数/客户不同口径不互换，连续月增10%以上无基数不反推ARR，AI功能须逐产品核。"
|
||||
},
|
||||
{
|
||||
"id": "TC26HW5-VALENE-1",
|
||||
"companyId": "TC-VALENE",
|
||||
"title": "Valene原始临床工作流平台",
|
||||
"url": "https://valenehealth.com/",
|
||||
"publishedAt": null,
|
||||
"accessedAt": "2026-10-31",
|
||||
"kind": "官方/公司自述：2026健康组原始资料复核",
|
||||
"summary": "临床文书/HCC、预授权、接诊、依从性和RCM语音/文字Agent及EHR接入；兼及心理健康机构。",
|
||||
"limitation": "等待时间/运营成本/收入机会改善为厂商主张非独立测试或自家公司收入，未披露当前价格、合同额/经常性。"
|
||||
},
|
||||
{
|
||||
"id": "TC26HW5-VALENE-2",
|
||||
"companyId": "TC-VALENE",
|
||||
"title": "Valene原始公司年与规模",
|
||||
"url": "https://www.linkedin.com/company/valene-health",
|
||||
"publishedAt": null,
|
||||
"accessedAt": "2026-10-31",
|
||||
"kind": "官方/公司自述：2026健康组原始资料复核",
|
||||
"summary": "公司自报2025、NewYork及11—50范围，PanagiotisKakatsos/ItaloPerez等，临床Agent工作流。",
|
||||
"limitation": "公司自报非独立注册，Techstars名录1—10与公司11—50范围并存不取中点；HIPAA/SOC2审计声明无原始报告未独立验证。"
|
||||
},
|
||||
{
|
||||
"id": "TC26HW5-VALENE-3",
|
||||
"companyId": "TC-VALENE",
|
||||
"title": "Valene原始加速机构成立字段",
|
||||
"url": "https://jobs.techstars.com/companies/valene-health",
|
||||
"publishedAt": null,
|
||||
"accessedAt": "2026-10-31",
|
||||
"kind": "官方/公司自述：2026健康组原始资料复核",
|
||||
"summary": "Techstars原始名录链接valenehealth.com并列foundedin2025、PreSeed及1—10范围。",
|
||||
"limitation": "投资机构名录非实时注册摘录；不将参赛/融资当收入，第三方聚合2024未经原始登记补证，不据其重置当前2025自报。"
|
||||
},
|
||||
{
|
||||
"id": "TC26HW5-VALENE-4",
|
||||
"companyId": "TC-VALENE",
|
||||
"title": "Valene原始平台与诊疗主体条款",
|
||||
"url": "https://valenehealth.com/terms-conditions/",
|
||||
"publishedAt": null,
|
||||
"accessedAt": "2026-10-31",
|
||||
"kind": "官方/公司自述：2026健康组原始资料复核",
|
||||
"summary": "条款列VALENEHEALTHINC非医疗提供者，为SolasHealthPC提供技术/行政支持，诊疗关系由持牌Provider建立。",
|
||||
"limitation": "条款旧心理照护/招聘措辞与现临床Agent定位分列，法律实体沿革未独立核实；医生/关联诊疗费用不是自动归软件净费，不采错误热线等无关页文。"
|
||||
},
|
||||
{
|
||||
"id": "TC26HW5-VIRTUOSIS-1",
|
||||
"companyId": null,
|
||||
"title": "Virtuosis原始产品与计费方式",
|
||||
"url": "https://www.virtuosis.ai/",
|
||||
"publishedAt": null,
|
||||
"accessedAt": "2026-10-31",
|
||||
"kind": "官方/公司自述：2026健康组原始资料复核",
|
||||
"summary": "声学特征而非语义分析，Teams/Web/API交付，按量月/年计划可直接或经Microsoft伙伴计费，试用credits。",
|
||||
"limitation": "无报价/实收合同不推ARR；Logo/证言不当已付费数/独立诊断验证，30秒输出不等医疗准确率，未录音或调用API。"
|
||||
},
|
||||
{
|
||||
"id": "TC26HW5-VIRTUOSIS-2",
|
||||
"companyId": null,
|
||||
"title": "Virtuosis原始公司年",
|
||||
"url": "https://www.linkedin.com/company/virtuosis-ai/",
|
||||
"publishedAt": null,
|
||||
"accessedAt": "2026-10-31",
|
||||
"kind": "官方/公司自述：2026健康组原始资料复核",
|
||||
"summary": "同域公司自报2022、Lausanne及11—50范围，EPFLspin-off、LaraGervaise等，健康/沟通声学生物标记。",
|
||||
"limitation": "自报非独立登记，7关联账户不当员工数；Microsoft年度奖不作技术/财务审计或医疗许可。"
|
||||
},
|
||||
{
|
||||
"id": "TC26HW5-VIRTUOSIS-3",
|
||||
"companyId": null,
|
||||
"title": "Virtuosis原始大学2022项目",
|
||||
"url": "https://www.epfl.ch/innovation/startup/programs/blaze/2022-iii/",
|
||||
"publishedAt": null,
|
||||
"accessedAt": "2026-10-31",
|
||||
"kind": "官方/公司自述：2026健康组原始资料复核",
|
||||
"summary": "EPFL2022Trailblazers列Virtuosis视频会议声学ML、LaraGervaise/EdoardoGiudice及SaaS定位。",
|
||||
"limitation": "机构旧项目可证明范围前活动，非当前所有疾病检测已验证；应用研究/试点不当商业合同额。"
|
||||
},
|
||||
{
|
||||
"id": "TC26HW5-VOYTHOS-1",
|
||||
"companyId": null,
|
||||
"title": "Voythos原始主动脉AI阶段",
|
||||
"url": "https://www.voythos.ai/",
|
||||
"publishedAt": null,
|
||||
"accessedAt": "2026-10-31",
|
||||
"kind": "官方/公司自述：2026健康组原始资料复核",
|
||||
"summary": "AortaNavigator监测/筛查与Pythia多模态模型分列，Pythia明确INDEV、pursuingFDAclearance；自述50万纵向记录。",
|
||||
"limitation": "追求许可不是获批；模型数据量非付费用户，大学医院支持不当独立产品有效性/收入，未运行临床推演。"
|
||||
},
|
||||
{
|
||||
"id": "TC26HW5-VOYTHOS-2",
|
||||
"companyId": null,
|
||||
"title": "Voythos原始大学旧项目",
|
||||
"url": "https://www.linkedin.com/posts/rice-alliance-for-technology-and-entrepreneurship_founderspotlightseries-startup-bayoustartupsummer-activity-7075174574346145792-1Xt3",
|
||||
"publishedAt": null,
|
||||
"accessedAt": "2026-10-31",
|
||||
"kind": "官方/公司自述：2026健康组原始资料复核",
|
||||
"summary": "RiceAlliance原始2023活动列JoeMakoid为Voythos共同创始人、Class11OwlSpark，医师EMR陪伴/工作流及LifeXPitch20000美元奖。",
|
||||
"limitation": "原始项目非精确法律注册，但范围前同团队同事业；奖项非销售，新主动脉模型不重置公司年。"
|
||||
},
|
||||
{
|
||||
"id": "TC26HW5-VOYTHOS-3",
|
||||
"companyId": null,
|
||||
"title": "Voythos原始加速机构创始人访谈",
|
||||
"url": "https://www.techstars.com/blog/startup-spotlight/transforming-cardiovascular-care-with-joe-makoid-voythos",
|
||||
"publishedAt": null,
|
||||
"accessedAt": "2026-10-31",
|
||||
"kind": "官方/公司自述：2026健康组原始资料复核",
|
||||
"summary": "2026-02-25创始人访谈称购160万患者数据、训练某些结果95%以上准确率，2026目标5—10机构部署，并在即时收入/临床验证路线间推进。",
|
||||
"limitation": "创始人训练自述非独立验证，机构目标不是已部署/付费；购买数据是成本非收入，早期模型与当前产品/数据口径不同不硬加总。"
|
||||
},
|
||||
{
|
||||
"id": "TC26HW5-WOAFY-1",
|
||||
"companyId": null,
|
||||
"title": "Woafy原始网站与别名对应",
|
||||
"url": "https://woafy.pet/",
|
||||
"publishedAt": null,
|
||||
"accessedAt": "2026-10-31",
|
||||
"kind": "官方/公司自述：2026健康组原始资料复核",
|
||||
"summary": "原www工具不可用，根域可读且直接链接WoafMeow旧品牌站；智能犬床无接触心率/呼吸/体重等感知和App报告。",
|
||||
"limitation": "3500家长宣传/招募非付费数，宠物健康/疼痛检测为厂商描述未独立兽医验证；床/配件/社区服务与软件净费分开。"
|
||||
},
|
||||
{
|
||||
"id": "TC26HW5-WOAFY-2",
|
||||
"companyId": null,
|
||||
"title": "Woafy原始公司年与研发状态",
|
||||
"url": "https://www.linkedin.com/company/woafypet",
|
||||
"publishedAt": null,
|
||||
"accessedAt": "2026-10-31",
|
||||
"kind": "官方/公司自述：2026健康组原始资料复核",
|
||||
"summary": "同域公司自报2024、LosAngeles及11—50范围，明确formerlyWoafmeow；早期产品验证/订阅警报，筹备Kickstarter。",
|
||||
"limitation": "自报非独立登记；18000睡眠夜/89%beta自报/候补不作实际销售，免费AI订阅赠品不推未来经常收入；第三方1—10M估算未采。"
|
||||
},
|
||||
{
|
||||
"id": "TC26HW5-WOAFY-3",
|
||||
"companyId": null,
|
||||
"title": "Woafmeow原始开发者身份",
|
||||
"url": "https://play.google.com/store/apps/details?hl=en&id=com.woafmeow.app",
|
||||
"publishedAt": null,
|
||||
"accessedAt": "2026-10-31",
|
||||
"kind": "官方/公司自述：2026健康组原始资料复核",
|
||||
"summary": "GooglePlay开发者提交页列WoafMeowInc、Walnut及woafmeow支持域，2025-09更新的宠物AI健康App。",
|
||||
"limitation": "App更新不是成立，开发者隐私/兽医批准说法非平台独立认证；旧App与新床具体法律沿革及合同待核，未下载/收集宠物或个人资料。"
|
||||
}
|
||||
],
|
||||
"reviews": [
|
||||
@@ -100016,6 +100222,43 @@
|
||||
"TC26HW4-TIMETELLER-3"
|
||||
],
|
||||
"handling": "Provision明确未获FDA许可，测试计划评审非批准；Sound故事由人写/声音用AI，牙科早期合作不当临床验证；TimeTeller错误相对路径和可读正确路径分列。具名196登记/5健康待登记及Nunatak空锚，全部来源未完成。"
|
||||
},
|
||||
{
|
||||
"id": "TC26HW5-R-REVENUE",
|
||||
"type": "医疗软件、语音/宠物硬件与诊疗净费",
|
||||
"company": "2026健康末5项",
|
||||
"scope": "dataset",
|
||||
"summary": "Valene医疗工作流净软件费与SolasHealthPC诊疗费拆分，Uhura语音器械、Woafy宠物床/配件与订阅、Virtuosis按量月年计划、Voythos研发/部署路线分列。",
|
||||
"evidenceIds": [
|
||||
"TC26HW5-UHURA-1",
|
||||
"TC26HW5-VALENE-1",
|
||||
"TC26HW5-VIRTUOSIS-1",
|
||||
"TC26HW5-VOYTHOS-1",
|
||||
"TC26HW5-WOAFY-1",
|
||||
"TC26HW5-VALENE-4"
|
||||
],
|
||||
"handling": "无收入观测新增。测试者/设备销量/睡眠夜/候补、模型训练数据与赠送credits不作软件ARR；医院收入机会改善不当自身营收，融资/奖项及未来机构目标不年化。"
|
||||
},
|
||||
{
|
||||
"id": "TC26HW5-R-ROSTER",
|
||||
"type": "2026具名201项访问闭合及残余缺项",
|
||||
"company": "2026总入口具名201URL",
|
||||
"scope": "dataset",
|
||||
"summary": "最后5原网址已登记，具名201唯一URL全部有候选访问记录；4旧事业暂范围外，Valene公司及Techstars2025暂关联。",
|
||||
"evidenceIds": [
|
||||
"TC26AG-INDEX",
|
||||
"TC26HW5-UHURA-2",
|
||||
"TC26HW5-VALENE-2",
|
||||
"TC26HW5-VALENE-3",
|
||||
"TC26HW5-VALENE-4",
|
||||
"TC26HW5-VIRTUOSIS-2",
|
||||
"TC26HW5-VIRTUOSIS-3",
|
||||
"TC26HW5-VOYTHOS-2",
|
||||
"TC26HW5-VOYTHOS-3",
|
||||
"TC26HW5-WOAFY-2",
|
||||
"TC26HW5-WOAFY-3"
|
||||
],
|
||||
"handling": "201登记是访问/候选对账，不等201家新AI公司、主体年/AI主营/财务已全核。Valene2025与二手2024/旧条款沿革待原始注册补证；Woafy改名/根域和Voythos旧项目保留。Nunatak空锚仍未对应，2025SaveFirst及全部来源档案/合同缺项未完成。"
|
||||
}
|
||||
],
|
||||
"coverage": {
|
||||
@@ -112089,6 +112332,97 @@
|
||||
]
|
||||
}
|
||||
]
|
||||
},
|
||||
{
|
||||
"id": "TC-2026-battlefield-health-5",
|
||||
"sourceId": "S02",
|
||||
"url": "https://techcrunch.com/2026/08/20/the-2026-startup-battlefield-200-is-here-see-who-made-the-cut/",
|
||||
"accessedAt": "2026-10-31",
|
||||
"scope": "健康末5项原网址核对：Valene2025关联，Uhura2022、Virtuosis2022、Voythos原始2023项目、Woafy2024暂范围外。具名201全部有候选访问记录，Nunatak空锚与身份/合同缺项及全来源研究仍未完成。",
|
||||
"complete": false,
|
||||
"records": [
|
||||
{
|
||||
"id": "TC26-HW5-UHURA",
|
||||
"name": "Uhura Bionics",
|
||||
"url": "http://www.uhura.pl",
|
||||
"categoryId": "C10",
|
||||
"kind": "company",
|
||||
"profileStatus": "readable",
|
||||
"status": "outside-cohort",
|
||||
"note": "原始公司自报2022及官网2023—25研发/2024起销售暂范围外；语音设备与未来AI栈、当前增音器分开。",
|
||||
"evidenceIds": [
|
||||
"TC26AG-INDEX",
|
||||
"TC26HW5-UHURA-1",
|
||||
"TC26HW5-UHURA-2"
|
||||
]
|
||||
},
|
||||
{
|
||||
"id": "TC26-HW5-VALENE",
|
||||
"name": "Valene Health",
|
||||
"url": "https://valenehealth.com/",
|
||||
"categoryId": "C07",
|
||||
"kind": "company",
|
||||
"profileStatus": "readable",
|
||||
"status": "linked",
|
||||
"note": "公司及Techstars原始名录均2025，暂按自报关联C07医疗工作流AI；法律登记/旧平台主体沿革与第三方年份差异仍待核。",
|
||||
"evidenceIds": [
|
||||
"TC26AG-INDEX",
|
||||
"TC26HW5-VALENE-1",
|
||||
"TC26HW5-VALENE-2",
|
||||
"TC26HW5-VALENE-3",
|
||||
"TC26HW5-VALENE-4"
|
||||
],
|
||||
"companyId": "TC-VALENE"
|
||||
},
|
||||
{
|
||||
"id": "TC26-HW5-VIRTUOSIS",
|
||||
"name": "Virtuosis",
|
||||
"url": "https://www.virtuosis.ai",
|
||||
"categoryId": "C07",
|
||||
"kind": "company",
|
||||
"profileStatus": "readable",
|
||||
"status": "outside-cohort",
|
||||
"note": "公司自报2022与EPFL2022项目对应暂范围外；声学健康/沟通洞察，旧员工健康到新疾病筛查定位不重置成立。",
|
||||
"evidenceIds": [
|
||||
"TC26AG-INDEX",
|
||||
"TC26HW5-VIRTUOSIS-1",
|
||||
"TC26HW5-VIRTUOSIS-2",
|
||||
"TC26HW5-VIRTUOSIS-3"
|
||||
]
|
||||
},
|
||||
{
|
||||
"id": "TC26-HW5-VOYTHOS",
|
||||
"name": "Voythos",
|
||||
"url": "http://voythos.ai",
|
||||
"categoryId": "C07",
|
||||
"kind": "company",
|
||||
"profileStatus": "readable",
|
||||
"status": "outside-cohort",
|
||||
"note": "Rice原始2023创业项目已列Voythos/JoeMakoid，暂旧事业范围外；2025加速不等成立，精确注册仍未核。",
|
||||
"evidenceIds": [
|
||||
"TC26AG-INDEX",
|
||||
"TC26HW5-VOYTHOS-1",
|
||||
"TC26HW5-VOYTHOS-2",
|
||||
"TC26HW5-VOYTHOS-3"
|
||||
]
|
||||
},
|
||||
{
|
||||
"id": "TC26-HW5-WOAFY",
|
||||
"name": "WoafMeow",
|
||||
"url": "https://www.woafy.pet",
|
||||
"categoryId": "C10",
|
||||
"kind": "company",
|
||||
"profileStatus": "readable",
|
||||
"status": "outside-cohort",
|
||||
"note": "原始公司自报2024、Woafmeow改WoafyPet并反链原域，暂范围外；移动App到宠物床硬件/云分析转型不重置成立。",
|
||||
"evidenceIds": [
|
||||
"TC26AG-INDEX",
|
||||
"TC26HW5-WOAFY-1",
|
||||
"TC26HW5-WOAFY-2",
|
||||
"TC26HW5-WOAFY-3"
|
||||
]
|
||||
}
|
||||
]
|
||||
}
|
||||
],
|
||||
"directoryRechecks": [
|
||||
|
||||
File diff suppressed because one or more lines are too long
@@ -1,5 +1,5 @@
|
||||
{
|
||||
"sourceVersion": "2026-10-31-tc26-health-4",
|
||||
"sourceVersion": "2026-10-31-tc26-health-5",
|
||||
"asOf": "2026-10-31",
|
||||
"metric": "platform-mrr-usd",
|
||||
"sampleUnit": "product-or-business",
|
||||
|
||||
Reference in New Issue
Block a user